BioAnalytical expansion at BioOutsource
23 November 2011
The BioAnalytical division of BioOutsource Ltd. has recently been expanded in terms of laboratory space, equipment and staff. The provision of assays to help clients support the development of biologics requires an ever expanding number of techniques which has resulted in the need for greater resources. BioOutsource is a key supplier of assays to both innovative biologic products as well as the Biosimilar / Biobetters market where we have developed a number of validated techniques for clients “off the shelf” requirements. To assist with the detection of Anti-Drug Antibodies, BioOutsource has recently introduced the Mesoscale Discovery (MSD) technology. In a recent publication authored by a group from Pfizer the MSD outperformed traditional ELISA techniques in a number of ways. MSD is known to have less matrix effects, is more sensitive, has a larger dynamic range and will have better tolerance for the detection of antibodies in the presence of therapeutic drug. All of which make this “the technology to use” in clinical trial assessments. Increasing the BioAnalytical team with Ph.D. and graduate scientists has expanded our expertise and doubled our capacity to take on client projects which can now run 20 simultaneous studies. Biooutsource is sure that this commitment to the drug development service is an important improvement on that currently available in the market.